Satellite Symposia

Satellite symposia descriptions will be posted as they are confirmed. Please visit this page regularly for updated information.  

Thursday, April 25

Satellite Symposium - Eli Lilly (17:00 - 18:15)

Collaborate & Connect in the care of HR+/HER2-mBC: Taking a multidisciplinary approach to optimizing treatment with CDK4/6 inhibitors

Dr. Sandy Sehdev, Ottawa Cancer Center, Ottawa, ON
Dr. Scott Edwards, Eastern Health, St. John’s, NB
Massey Nematollahi, William Osler, Brampton, ON

In contrast to treatments like chemotherapy, toxicities associated with CDK4/6 inhibitors can be limited by dose reductions and modifications. Therefore, it is critical to have multiple healthcare providers monitoring patients throughout the treatment process to ensure the early identification of any side effects or treatment complications. Open communication amongst a patient’s multi-disciplinary oncology team ensures all stakeholders can quickly act upon the onset of any adverse events to:

  • Minimize the impact of adverse events
  • Avoid prolonged treatment interruptions
  • Maintain patient confidence in their treatment plan

Learning Objectives:

  1. Identify the role that new evidence and treatment options play in the management of HR+/HER2-mBC;
  2. Implement practical strategies around side effect management, monitoring requirements, and dosing recommendations for CDK4/6 inhibitors; and
  3. Discuss best practices to optimize the impact of multidisciplinary teams in HR+/HER2-mBC.

Friday, April 26

Satellite Symposium - LEO Pharma (07:00-08:30)

How Drug-Drug-Interactions and Adverse Event Profiles should Influence Optimal Choice of Anticoagulant Therapy in Cancer Patients

Thomas R.J. McFarlane, BScPhm, PharmD, RPh, Clinical Lecturer/Pharmacy Teaching Fellow, University of Waterloo, Waterloo, ON
Sandy Sehdev, MD, FRCPC, Medical Oncologist, The Ottawa Hospital Cancer Centre, Ottawa, ON

Venous thromboembolism is a significant source of morbidity and mortality in cancer patients, with a rapidly evolving treatment landscape. Multiple options are available to treat this condition and it is now recognized that patient selection is critical to ensure positive outcomes. 

The goal of this symposium is to help healthcare providers understand how to tailor anticoagulation in the context of the latest clinical trials. 

Key safety issues when selecting therapy to treat cancer-associated thrombosis will be highlighted, with a particular focus on the potentially underappreciated risks arising from drug-drug interactions and adverse events related to common cancer treatment (and supportive) regimens.

Learning Objectives:

  1. Discuss how to mitigate risks associated with anticoagulation treatment in Cancer Associated Thrombosis;
  2. Raise awareness of how the risk of Drug-Drug-Interactions may impact efficacy and safety of anticoagulation; and
  3. Review how Adverse Event profiles of concomitant medications may impact safety of anticoagulation. 

Satellite Symposium - Apobiologix (8:45 - 10:15)

Practical Considerations When Incorporating Biosimilars into Oncology Practice

Although there are only a handful of biosimilars in oncology approved by Health Canada to date, there are many more in the pipeline. Considering early adoption and expectations of an increasing number of biosimilars, the Canadian oncology community is anticipating the necessary changes. While the regulatory agency has an established framework for biosimilar approvals and payers have started to shape reimbursement policies, there are additional aspects that providers and institutions will face that require thoughtful consideration. How will biosimilars be incorporated efficiently, effectively and seamlessly into practice? What will it mean for the greater healthcare ecosystem? This symposium will explore and debate practical aspects related to the use of biosimilars in oncology with the goal of helping shape a solution through awareness and discussion.

Satellite Symposium - Pfizer Injectables (14:00 - 15:30)

How to tailer anticoagulation in cancer-associated thrombosis: LMWH or DOAC?

Learning Objectives:

  • Review latest data on use of new oral antiagulants for cancer-associated thrombosis (CAT);
  • Choose optimal VTE treatment in CAT patients based on latest evidence; and
  • Understsand the importance of the role of the pharmacists in the management of CAT.

Satellite Symposium - Ipsen (15:45 - 17:15)

Advances in the Management of locally Advanced Renal Cell Carcinoma (aRCC)

Learning Objectives:

  • To facilitate peer to peer exchange and sharing through clinical case discussions in Advanced Renal Cell Carcinoma (aRCC);
  • To present clinical evidence for new therapies in the treatment of aRCC including a new multi-targeted TKI therapy; and
  • To review and discuss optimal patient management in aRCC.

Satellite Symposium - AbbVie (17:30 - 19:00)

Dr. Versha Banerji
Lily Spasic

This program aims to inform the audience of recent treatment advances in CLL, including data on patient outcomes in regards to safety and efficacy. The symposium will also address how these changes are impacting the healthcare system with mention of potential solutions to ensure optimal outcomes and system sustainability. 

Saturday, April 27

Satellite Symposium - BD (7:00 - 8:30)

Dr. Chun-Yip Hon, PhD, CPHI(C), CRSP, CIH, Associate Professor, School of Occupational and Public Health, Ryerson Univeristy, Toronto, ON

Healthcare Workers' Exposure to Antineoplastic (Hazardous) Drugs

According to CAREX Canada, about 75,000 Canadian healthcare workers, including pharmacists, physicians and other caregivers, are potentially exposed to hazardous drugs1.   This exposure is putting them at risk of both short- and long-term health issues such as headaches, hair loss, nausea, reproductive problems,2 genetic effects and even cancer.3   Occupational exposure is primarily through contact with the drugs (IV bags or the vials) or indirectly through touching a drug-contaminated surface.  Drug contamination has been found on surfaces throughout the hospital medical circuit and is not just isolated to the pharmacy and drug administration units.4   To minimize these risks, healthcare facilities should comply with safe drug handling standards, guidelines and recommendations including regular surface wipe testing or environmental monitoring.  In addition to assessing risk of exposure to hazardous drugs, surface wipe testing can be used to evaluate cleaning efficacy as well as determine the effectiveness of control measures. The National Association of Pharmacy Regulatory Authorities (NAPRA) recommends hazardous drug contamination should be measured at least every 6 months.5 

1. Carex Canada, 2018.  https://www.carexcanada.ca/en/antineoplastic_agents/occupational_estimate/
2. Connor TH, Lawson CC, Polovich M, McDiarmid MA. Reproductive health risks associated with occupational exposures to antineoplastic drugs in health care settings: a review of the evidence. J Occup Environ Med. 2014;56(9):901-910.
3. Hansen J, Olsen JH. Cancer morbidity among Danish female pharmacy technicians. Scand J Work Environ Health. 1994;20(1):22-26.
4. Hon CY, Teschke K, Chu W, Demers P, Venners S. Antineoplastic drug contamination of surfaces throughout the hospital medication system in Canadian hospitals. Journal of Occupational and Environmental Hygiene. 2013;10(7):374-83.
5. National Association of Pharmacy Regulatory Authorities. (2016). Model Standards for Pharmacy Compounding of Hazardous Sterile Preparations. Ottawa: NAPRA.

Learning Objectives:

  • What is surface contamination?;
  • Review results from the literature;
  • Occupational exposure limits;
  • How to test for surface comtamination;
  • Way to reduce surface contamination; and
  • Policy considerations (to reduce exposure).

Sunday, April 28

Satellite Symposium - Baxter (7:00 - 8:30)

Understanding and Implementing Dose Banding: Approaches to Manage Drug Wastage Costs When Complying with NAPRA BUD Requirements

Dr. Alicia Wall, Regional Manager of Oncology Pharmacy Services, Eastern Health, Newfoundland
Dr. Darryl Boehm, Director of Pharmacy, Saskatchewan Cancer Agency, Saskatchewan

The incidence of cancer diagnoses in Canada is rising, resulting in an increase in the number of chemotherapy drugs.  The increasing cost of chemotherapy drugs puts a demand on healthcare resources.  The NAPRA compounding 6-hour beyond use date standard for single dose vials is expected to increase drug expenditures.  Cancer Care Ontario recommends dose banding to help with system efficiencies, reduce wait times and minimize drug waste.  This symposium will review the benefits of dose banding, describe the evidence to support dose banding and outline a practical approach and evaluation of implementing dose banding at Eastern Health and Saskatchewan Cancer Agency.